ERBB2 and neoplasm: Compared to 2018/2019, neo-adjuvant chemotherapy was less likely for patients diagnosed during transition with a stage I, stage II, HR+/HER2−, or HR−/HER2− tumor (odds ratio (OR) 0.24, 95%CI 0.11–0.53; OR 0.63, 95%CI 0.47–0.68; OR 0.55, 95%CI 0.41–0.75; OR 0.46, 95%CI 0.27–0.77, respectively), while neo-adjuvant chemotherapy was more likely for patients diagnosed during care restart with a stage I, stage II, HR+/HER2+, or HR−/HER2− (OR 1.88, 95%CI 1.29–2.75; OR 1.36, 95%CI 1.11–1.68; OR 2.11, 95%CI 1.32–3.38; OR 2.49, 95%CI 1.55–4.00, respectively) (Tables 3 and 4).